1. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2);Cardoso;Ann Oncol,2014
2. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial;Aebi;Lancet Oncol,2014
3. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group;Mouridsen;J Clin Oncol,2001
4. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study;Finn;Lancet Oncol,2014
5. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial;Leo;J Natl Cancer Inst,2012